Preterm Birth Control Market Growth and Forecast by 2025

The global preterm birth control market is expected to reach US$ 1,809.0 Mn in 2025 from US$ 1,190.5 Mn in 2017. The market is estimated to grow with a CAGR of 4.9% from 2018-2025.

North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant rate in Asia Pacific (APAC) region during the forecast period. The Asia Pacific per-term birth control market is expected to grow with CAGR of 5.1% to US$ 325.6 Mn in 2025 from US$ 222.4 Mn in 2017.

Market Insights

Increasing Number of Preterm Births

There has been a gradual increase in the number of preterm births from last few years. As per the World Health Organization (WHO), premature birth is a leading cause of death among the child below 5 years of age. It may be due to early induction of labor or caesarean birth. Multiple pregnancies, infections and chronic conditions such as diabetes and high blood pressure are others common causes of preterm births. As per the Centers for Disease Control and Prevention (CDC), reduction in preterm birth was observed from 2007-2014. In 2015, low birth weight and preterm birth accounted for about 17% of infant deaths. However, the number increased during 2016, with racial and ethnic differences. In the US, 1 of every 10 infants born was a preterm birth.

Customize This Report To Suit Your Requirement

Get FREE CUSTOMIZATION

Initiatives towards Prevention of Preterm Birth

A number of government and non-government organizations are engaged increasing awareness about preterm birth in various countries across the globe. Organizations such as CDC has implemented strategies to reduce preterm births. These strategies includes provision of healthcare services before and between pregnancies; determining population at the risk of preterm delivery and provide immediate treatment, discouraging deliveries before 39 weeks without a medical need; and preventing unintended pregnancies by waiting for at least 18 months between pregnancies.

Stringent Regulatory Framework

Regulatory authorities such as Food & Drug Administration (FDA), European Medicine Agency (EMA) and others has consistently shown a tough stance towards pharmaceutical can biotechnology manufacturers. The market players must comply with the requirement and guidelines of FDA and other regulatory authorities and should constantly keep a check over time to time changes made in these guidelines. The manufacturers of pharmaceutical drugs and medical devices must abide by these regulations pertaining to current good manufacturing practices (cGMP) as well as good laboratory practices (GLP) in order to assure proper design, monitoring, and control of manufacturing processes and facilities. Furthermore, any deviations from the registered protocols, demands and requirements of these guidance leads to termination of the clinical trials undertaken by the pharmaceutical companies.

Additionally, FDA also requires strong safety monitoring and a strict dispensing plan to be followed by the manufacturer. Non-compliance by the manufacturers affects the sales of the products in the market and may lead to the recalls for marketed products due to instances recorded for deficit of the promises in the function and performance of the product or therapeutic may tarnish the company’s reputation risking its future growth. In case of clinical trials for development of therapeutics for preterm birth control, the FDA and other regulatory bodies have strict regulations due to which it is difficult for the manufacturers to pool in pregnant patients generating lack of working models. This in turn results into rejection of trials and can thus act as hindrance to the market growth.

Product Insights

The pre-term birth control market by treatment method is segmented into pharmaceutical treatment and devices. The pharmaceutical treatment segment is poised to grow with a largest market share of 55.6% in 2017. The market for pharmaceutical treatment is anticipated to surge during the forecast period from 2017 to 2025, at a significant rate.

Collaborations/ acquisitions were observed as the most adopted strategy in global pre-term birth control industry. Few of the product launches and agreements made by the players in the market are listed below;

2018: CooperSurgical had acquired the assets of The LifeGlobal Group and its affiliates. The LifeGlobal Group is a leading global provider of in-vitro fertilization devices.

Preterm Birth Control

Published Report - Preterm Birth Control Market Report Scope

Published Report - Preterm Birth Control Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - Preterm Birth Control Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Pre-term Birth Control – Market Segmentation

By Treatment method

• Devices
• Cervical Cerclage
• Vaginal Pessaries
• Pharmaceutical treatment

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • U.K
• Asia Pacific
  • Japan
  • China
  • India
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
• South & Central America
  • Argentina
  • Brazil

Company Profiles

• Cooper Surgical
• Medgyn Products
• Integra Life sciences Corporation
• Panpac Medical Corp.
• Dr. Arabin GMBH & Co. KG
• Amag Pharmaceuticals
• Ben Way Enterprises Sdn Bhd
• Personal Medical Corp.
• Bioteque America Inc.
• Bliss Gvs Pharma Ltd.